ArticleAnnals of biomedical engineering2025
Optimized FDA Blood Pump: A Case Study in System-Level Customized Ventricular Assist Device Designs.
Article in Annals of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe design and development of ventricular assist devices have heavily relied on computational tools, particularly computational fluid dynamics (CFD), since the early 2000s. However, traditional CFD-based optimization requires costly trial-and-error approaches involving multiple design cycles. This study aims to propose a more efficient VAD design and optimization framework that overcomes these limitations.
methodsWe developed a system- and component-level ventricle assist device optimization approach by coupling a lumped parameter cardiovascular physiology model with parametric turbomachinery, volute design, and blade path generation packages. The framework incorporates pump hydrodynamic losses and is validated against experimental data from six distinct blood pump designs and CFD simulations. The optimization framework allows for the specification of both physiology-related and device-related objective functions to generate optimized blood pump configurations over a large parameter space.
resultsThe optimization was applied to the U.S. Food and Drug Administration (FDA) benchmark blood pump as the baseline design. Results showed that an optimized FDA pump, maintaining the same cardiac output and aortic pressure, achieved a ~ 32% reduction in blade tip velocity compared to the baseline, resulting in an ~ 88% reduction in hemolysis. Additionally, an alternative design with a 40% reduction in blood-wetted area was generated while preserving the baseline pressure and flow.
conclusionThe proposed optimization framework improves device development efficiency by shortening the design cycle and enabling hydrodynamically optimized pumps that perform well across diverse patient hemodynamics. The optimized pump designs are available as open-source resources for further research and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.